🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jibran Ahmed

National Institutes of Health

ORCID: 0000-0002-3412-7689

Also affiliated with The University of Texas MD Anderson Cancer Center, National Cancer Institute, Center for Cancer Research

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer”.

A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer

Gynecologic Oncology(2025)10.1016/j.ygyno.2024.12.019
N/A
0.343DataRank · unranked
7 citations

Bettzy Stephen, Muhammad Rizwan Khawaja, Yali Yang, Israa Salih, Elizve Barrientos-Toro +11 more

584 Phase I/II study to evaluate the safety and tolerability of avelumab in combination with other anti-cancer therapies in patients with advanced malignancies

Regular and Young Investigator Award Abstracts(2023)10.1136/jitc-2023-sitc2023.0584
N/A
0DataRank · unranked
0 citations

Anne Knisely, Bettzy Stephen, Yali Yang, Juhee Song, Anas Alshawa +9 more

TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer

American Journal of Cancer Research(2024)10.62347/mqff6404
N/A
0DataRank · unranked
9 citations

Jibran Ahmed

RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study

Molecular Cancer(2024)10.1186/s12943-024-01982-4
N/A
0DataRank · unranked
2 citations

Jason Roszik, Jibran Ahmed, Carmelia Maria Noia Barretto, Mirella Nardo, Erick Campbell +9 more

Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancers

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-013252
N/A
0DataRank · unranked
1 citations

Geraldine O’Sullivan Coyne, Larry Rubinstein, Sarah J Shin, Naoko Takebe, Ashley Bruns +12 more

A phase 2 basket study of talabostat, a small‐molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers

Cancer(2025)10.1002/cncr.35728
N/A
0DataRank · unranked
4 citations

Filip Janku, Daniel D. Karp, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Timothy A. Yap +8 more

Phase 1 study of recombinant interleukin 15 in combination with nivolumab and ipilimumab in subjects with refractory cancers.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.2617
N/A
0DataRank · unranked
0 citations

Geraldine O’Sullivan Coyne, Ashley Bruns, Larry Rubinstein, Naoko Takebe, Sarah J. Shin +10 more

Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies

Cancer(2023)10.1002/cncr.35063
N/A
0DataRank · unranked
17 citations

Jibran Ahmed, Bettzy Stephen, Sarina A. Piha‐Paul, Daniel D. Karp, Abdulrazzak Zarifa +13 more

Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors (RARE CANCER) trial: RARE 2 talazoparib and temozolomide.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.3155
N/A
0DataRank · unranked
0 citations

Jennifer Zlott, Jared C. Foster, Sarah J. Shin, Geraldine O’Sullivan Coyne, Naoko Takebe +5 more